Fly News Breaks for December 8, 2015
WBC, MTN, UN, UL, TMO, SKT, OUTR, MYGN, LAMR, K, HSY, GALE, FEYE, FEIC, DEI, BBCN, ARES, A, ALE, BUD
Dec 8, 2015 | 09:44 EDT
Today's noteworthy upgrades include: AB InBev (BUD) upgraded to Buy from Reduce at HSBC...ALLETE (ALE) upgraded to Buy from Hold at Wunderlich...Agilent (A) upgraded to Buy from Neutral at Goldman...Ares Management (ARES) upgraded to Buy from Neutral at BofA/Merrill...BBCN Bancorp (BBCN) upgraded to Neutral from Underweight at Piper Jaffray...Douglas Emmett (DEI) upgraded to Outperform from Market Perform at BMO Capital...FEI Company (FEIC) upgraded to Buy from Neutral at Goldman...FireEye (FEYE) upgraded to Buy from Neutral at Citi...Galena (GALE) upgraded to Hold from Sell at Cantor...Hershey (HSY) upgraded to Buy from Hold at Argus...Kellogg (K) upgraded to Equal Weight from Underweight at Morgan Stanley...Lamar Advertising (LAMR) upgraded to Buy from Hold at Topeka...Myriad Genetics (MYGN) upgraded to Neutral from Sell at Goldman...Outerwall (OUTR) upgraded to Buy from Neutral at B. Riley...Tanger Factory (SKT) upgraded to Buy from Neutral at Goldman...Thermo Fisher (TMO) upgraded to Conviction Buy from Buy at Goldman...Unilever (UL) upgraded to Neutral from Underperform at Credit Suisse...Vail Resorts (MTN) upgraded to Buy from Neutral at Goldman...WABCO (WBC) upgraded to Buy from Hold at Stifel.
News For BUD;ALE;A;ARES;BBCN;DEI;FEIC;FEYE;GALE;HSY;K;LAMR;MYGN;OUTR;SKT;TMO;UL;UN;MTN;WBC From the Last 2 Days
TMO
Mar 19, 2024 | 07:35 EDT
Repligen Corporation (RGEN) announced the appointment to its Board of Directors of life sciences industry executive Maggie Pax. This appointment expands the size of Repligen's board from eight to nine members. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific (TMO), where, from 2016-2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business
UL
Mar 19, 2024 | 05:18 EDT
Unilever announced steps to accelerate its "Growth Action Plan" through the separation of Ice Cream and the launch of a productivity program. The board believes Unilever "should be increasingly focused on a portfolio of unmissably superior brands with strong positions in highly attractive categories that have complementary operating models. Ice Cream has a "very different operating model," and as a result the board has decided that the separation of Ice Cream "best serves the future growth of both Ice Cream and Unilever." Following separation, Unilever "will become a simpler, more focused company, operating four Business Groups across Beauty & Wellbeing, Personal Care, Home Care and Nutrition," the company said in a statement. In addition, Unilever said it will continue to optimize its portfolio within the four business groups towards higher growth spaces and through brands with global reach or significant potential to scale.
TMO
Mar 18, 2024 | 09:45 EDT
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's... To see the rest of the story go to thefly.com.
See Story HereTMO
Mar 18, 2024 | 07:28 EDT
Citi analyst Patrick Donnelly resumed coverage of Thermo Fisher with a Neutral rating and $620 price target. The analyst we sees the stock's current valuation as fair. The firm continues to view Thermo as a "well-entrenched diversified player" and believes management has mostly de-risked this year, but given the recent multiple expansion and its 2025 numbers below consensus, Citi has a Neutral rating on the name.